Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints

Journal of Neural Transmission

Volumn 118, Issue 2, 2011, Pages 259-262

  Antonell, Anna ^a   Fortea, Juan ^a   Rami, Lorena ^a   Bosch, Beatriz ^a   Balasa, Mircea ^a   Sánchez Valle, Raquel ^a   Iranzo, Alex ^a   Molinuevo, José Luis ^a   Lladó, Albert ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Alzheimer's disease; Biomarker; Cognitively normal subjects; CSF; Subjective memory complaint

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; PROTEIN P TAU 181; PROTEIN T TAU; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MEMORY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

EID: 79955930875     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-010-0534-0     Document Type: Article

References (19)

1. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65:1509-1517. doi:10.1001/archneur.65.11.1509
2. Bouwman FH, Schoonenboom NS, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, Scheltens P, van der Flier WM (2009) CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol Aging 30:1895-1901. doi:10.1016/j. neurobiolaging.2008.02.007
3. Braak H, Braak E, Bohl J, Reintjes R (1996) Age, neurofibrillary changes, A beta-amyloid and the onset of Alzheimer's disease. Neurosci Lett 210:87-90 (Pubitemid 26180122)
4. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-DRDA criteria. Lancet Neurol 6:734-746. doi:10.1016/S1474-4422(07)70178-3 (Pubitemid 47058377)
5. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P (2010) Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 9:1118-1127. doi:10.1016/S1474-4422(10)70223-4
6. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM (2007) Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64:343-349. doi:10.1001/archneur.64.3.noc60123 (Pubitemid 46425688)
7. Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM (2009) Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 65:176-183. doi:10.1002/ana.21559
8. Fortea J, Lladó A, Bosch B, Antonell A, Oliva R, Molinuevo JL, Sánchez-Valle R (2010) Cerebrospinal fluid biomarkers in Alzheimer's disease families with PSEN1 mutations. Neurodegenerative Dis (in press)
9. Iqbal K, Flory M, Khatoon S, Soininen H, Pirttila T, Lehtovirta M, Alafuzoff I, Blennow K, Andreasen N, Vanmechelen E, Grundke-Iqbal I (2005) Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann Neurol 58:748-757. doi:10.1002/ana.20639 (Pubitemid 41552550)
10. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9:119-128. doi:10.1016/S1474- 4422(09)70299-6
11. Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ (2007) CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69:631-639. doi:10.1212/01.wnl.0000267428.62582.aa (Pubitemid 47256004)
12. Mattsson N, Blennow K, Zetterberg H (2010) Interlaboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Clin Chem Lab Med 48:603-607. doi:10.1515/CCLM.2010.131
13. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67:122-131. doi:10.1002/ana.21843
14. Price JL, McKeel DW Jr, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC (2009) Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 30:1026-1036. doi:10.1016/j.neurobiolaging.2009.04.002
15. Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C, Skoog I, Wallin A, Wahlund LO, Marcusson J, Nagga K, Andreasen N, Davidsson P, Vanmechelen E, Blennow K (2001) Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 47:1776-1781 (Pubitemid 32881189)
16. Stomrud E, Hansson O, Blennow K, Minthon L, Londos E (2007) Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord 24:118-124. doi:10.1159/000105017 (Pubitemid 47094071)
17. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66:382-389. doi:10.1001/archneurol.2008.596
18. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Burger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009) Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 8:619-627. doi:10.1016/S1474- 4422(09)70139-5
19. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O (2010) CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 74:1531-1537. doi:10.1212/WNL.0b013e3181dd4dd8